Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Alone or in Combination in B-cell Non-Hodgkin Lymphoma
NCT02180711Phase 2Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Dec 2014
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Acerta Pharma. Started Dec 2014; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02180711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180711.